|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 120.78 USD | -1.50% |
|
-3.56% | +31.39% |
| Capitalization | 152B 131B 123B 114B 211B 13,692B 229B 1,433B 553B 6,466B 571B 559B 23,644B | P/E ratio 2025 * |
17.9x | P/E ratio 2026 * | 16.4x |
|---|---|---|---|---|---|
| Enterprise value | 165B 142B 133B 124B 229B 14,836B 249B 1,553B 600B 7,007B 619B 606B 25,620B | EV / Sales 2025 * |
5.64x | EV / Sales 2026 * | 5.26x |
| Free-Float |
99.9% | Yield 2025 * |
2.7% | Yield 2026 * | 2.82% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | -1.53% | ||
| 1 week | -3.56% | ||
| Current month | -3.56% | ||
| 1 month | -0.99% | ||
| 3 months | +5.49% | ||
| 6 months | +9.87% | ||
| Current year | +31.39% |
| 1 week | 120.38 |  | 126.23 |
| 1 month | 117.13 | | 128.7 |
| Current year | 88.57 | | 128.7 |
| 1 year | 88.57 | | 128.7 |
| 3 years | 62.07 | | 128.7 |
| 5 years | 56.56 | | 128.7 |
| 10 years | 56.56 | | 128.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 60 | 2019-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 55 | 2019-10-31 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | 63 | 2025-01-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 57 | 2016-08-18 |
| Director/Board Member | 72 | 2017-12-31 | |
| Director/Board Member | 71 | 2018-05-08 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 13.99% | 303 M€ | -21.70% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.51% | -3.56% | +29.96% | +37.95% | 152B | |
| -0.42% | -6.00% | +22.44% | +173.74% | 908B | |
| -0.15% | -2.22% | +35.31% | +13.17% | 488B | |
| -1.30% | -0.72% | +28.32% | +37.89% | 404B | |
| +0.26% | +1.14% | +21.30% | +0.44% | 331B | |
| +0.58% | -2.73% | +28.01% | +20.71% | 280B | |
| +0.19% | +2.49% | +18.48% | +24.80% | 256B | |
| -1.05% | -4.73% | -3.55% | -9.21% | 250B | |
| +1.24% | -2.33% | -59.84% | -31.25% | 212B | |
| -2.58% | -3.94% | +20.97% | +16.48% | 183B | |
| Average | -0.50% | -2.16% | +14.14% | +28.47% | 346.51B | |
| Weighted average by Cap. | -0.42% | -3.12% | +18.32% | +55.32% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 29.21B 25.11B 23.52B 21.92B 40.49B 2,629B 44.04B 275B 106B 1,242B 110B 107B 4,539B | 30.08B 25.86B 24.22B 22.58B 41.7B 2,707B 45.36B 283B 109B 1,279B 113B 110B 4,675B |
| Net income | 8.28B 7.12B 6.67B 6.22B 11.48B 745B 12.49B 78.01B 30.12B 352B 31.08B 30.42B 1,287B | 8.94B 7.69B 7.2B 6.71B 12.4B 805B 13.49B 84.24B 32.52B 380B 33.57B 32.85B 1,390B |
| Net Debt | 12.72B 10.93B 10.24B 9.54B 17.63B 1,144B 19.18B 120B 46.25B 541B 47.73B 46.71B 1,976B | 6.11B 5.25B 4.92B 4.59B 8.47B 550B 9.22B 57.58B 22.23B 260B 22.94B 22.45B 950B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 121.37 $ | -1.02% | 1,684,376 |
| 25-12-04 | 122.62 $ | -1.90% | 5,234,244 |
| 25-12-03 | 125.00 $ | +0.88% | 5,306,324 |
| 25-12-02 | 123.91 $ | -0.34% | 5,109,934 |
| 25-12-01 | 124.33 $ | -1.20% | 4,960,221 |
Delayed Quote Nasdaq, December 05, 2025 at 12:03 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GILD Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition